DoW Tick-Borne Disease Therapeutic/Diagnostic Research Award
Defense Health Agency Contracting Activity - DHACA · Military Medical Research and Development (12.420)
Posted 5 May 2026 · 21 days left
In plain terms
The US Defense Health Agency funds early-stage research on therapeutic treatments and diagnostic tools for Lyme disease and other tick-borne diseases, with a total programme budget of 2.65 million US dollars. Any type of US-based organisation or individual may apply with proposals due by 22 October 2026.
A generated summary of the donor's text; the original wording is below.
Summary
Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Therapeutic/Diagnostic Research Award (TDRA) is to support product-driven therapeutic and diagnostic development research aimed at reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or quality of life. Treatment-focused applications should be therapeutic evaluation studies designed to advance new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development. Diagnosis-focused applications should propose diagnostic approaches that will be readily integrated into clinical settings.
https://cdmrp.health.mil/pubs/press/2026/tbdrppreann
Excerpt from the donor's page. The full text, annexes and forms are on the original call.
Who can apply
- ngo_cso
- academia_research
- private_company
- government
- social_enterprise
- individual
- other
Eligibility and conditions
Show the eligibility text from the source
Applicant types: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"